SRE | ||
---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 55 Fair valued | |
PROFIT vs RISK RATING 1..100 | 55 | |
SMR RATING 1..100 | 69 | |
PRICE GROWTH RATING 1..100 | 57 | |
P/E GROWTH RATING 1..100 | 59 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IGF | SRE | |
---|---|---|
RSI ODDS (%) | 3 days ago76% | N/A |
Stochastic ODDS (%) | 3 days ago80% | 3 days ago47% |
Momentum ODDS (%) | 3 days ago83% | 3 days ago48% |
MACD ODDS (%) | 3 days ago86% | 3 days ago56% |
TrendWeek ODDS (%) | 3 days ago81% | 3 days ago52% |
TrendMonth ODDS (%) | 3 days ago79% | 3 days ago48% |
Advances ODDS (%) | 6 days ago83% | 6 days ago55% |
Declines ODDS (%) | 19 days ago81% | 20 days ago48% |
BollingerBands ODDS (%) | 3 days ago76% | 3 days ago57% |
Aroon ODDS (%) | 3 days ago80% | 3 days ago37% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
QIS | 22.62 | 0.41 | +1.85% |
Simplify Multi-QIS Alternative ETF | |||
VFMF | 137.29 | 1.09 | +0.80% |
Vanguard US Multifactor ETF | |||
ESML | 42.52 | 0.32 | +0.76% |
iShares ESG Aware MSCI USA Small-Cap ETF | |||
FTXH | 26.31 | N/A | +0.01% |
First Trust Nasdaq Pharmaceuticals ETF | |||
FMCE | 26.35 | N/A | N/A |
FM Compounders Equity ETF |
A.I.dvisor indicates that over the last year, IGF has been closely correlated with SRE. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if IGF jumps, then SRE could also see price increases.
A.I.dvisor indicates that over the last year, SRE has been loosely correlated with AES. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if SRE jumps, then AES could also see price increases.